°×С½ãÂÛ̳

The °×С½ãÂÛ̳ Cancer Institute Cancer Immunotherapy Accelerator (CITA) Network has been developed to maximise the potential of immunotherapeutics to cure more cancer sooner.

The CITA Network is funded by a and will serve as a hub, integrating key expertise across:

• °×С½ãÂÛ̳ (°×С½ãÂÛ̳) and °×С½ãÂÛ̳ Hospitals (°×С½ãÂÛ̳H)
• King’s College London (KCL)
• The Francis Crick Institute (FCI)
• Barts Cancer Institute
• The Royal Marsden Hospital (RMH)
• The Institute of Cancer Research (ICR)

This Network will provide a primary UK focus for understanding, implementing, and aiding cancer immunotherapy incorporating a state-of-the-art immune-monitoring and discovery core (IMDC) and Immuno-Oncology clinical trial training.

The aims of the Network are:

1.Deliver a capability package for all Centres to undertake immune monitoring of their patients

2.Drive immune discovery by investigating the mechanisms underpinning response, resistance and toxicity to immunotherapeutic approaches

3.Develop an iGEMM Core for the provision of mouse models of cancer that recapitulate the ITH and mutational diversity of cancer

4.Accelerate production of non-GMP recombinant biotherapeutic proteins and antibodies

5.Develop Immuno-Oncology Clinical Trial Training to train a new cadre of scientists and clinicians able to develop, improve, interpret and deliver relevant immunotherapy trials

  Image courtesy of Dr Andrew Furness (°×С½ãÂÛ̳)